Fusariosis
MONDO:0016426Fusariosis describes a superficial, locally invasive, disseminated infection with the pathogenic fungus species, Fusarium, often found in soil and water, which is mainly transmitted to humans through traumatic inoculation and that manifests with keratitis, onychomycosis and less frequently peritonitis and cellulitis. In the immunocompromised, disseminated fusariosis is more common and it manifests with refractory fever, skin lesions (ecthyma-like, target, and multiple subcutaneous nodules), severe myalgias and sino-pulmonary infections.
Also known as: Fusarium caused disease or disorder, Fusarium disease or disorder, Fusarium infection, Fusarium infectious disease
5 clinical trials for this condition and its sub-types, 4 tagged with Fusariosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New hope against deadly mold infections enters final testing
Disease control Recruiting nowThis study tests a new medicine called fosmanogepix for adults with serious mold infections that are hard to treat. About 234 people will join, receiving either the new drug or standard care. The main goal is to see if fewer people die by day 42. The study is currently recruiting…
Phase 3 • Sponsor: Basilea Pharmaceutica • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New rapid test could speed up sepsis diagnosis in ER
Knowledge-focused Recruiting nowThis study is testing a new rapid diagnostic device called In-Dx to quickly identify infections and antibiotic resistance in emergency patients with suspected sepsis. Researchers will compare the device's results to standard lab cultures using stored samples from 2,500 patients. …
Sponsor: Michigan State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Can immune monitoring unlock better treatments for deadly mold infections?
Knowledge-focused Recruiting nowThis study monitors the immune system of 20 adults with serious mold infections (like Aspergillus) to see how their T cells respond. The goal is to find out which patients might benefit from adding immunotherapy to standard antifungal drugs. Researchers will measure immune checkp…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC